Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

AstraZeneca plc. (5/8/18). "Press Release: Lynparza Tablets Receive EU Approval for the Treatment of Platinum-sensitive Relapsed Ovarian Cancer".

Region Region EU (European Union)
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 Merck & Co. Inc. (NYSE: MRK)
  Group Merck (US) (MSD) (Group)
Products Product Lynparza®
  Product 2 chemotherapeutic
Index term Index term AstraZeneca–Merck (US): cancer drugs, 201707– strategic oncology collab maximising combis of PARP + MEK inhibitors with PD-L1/PD1 medicines
Persons Person Fredrickson, David (AstraZeneca 201711 EVP Head of Oncology Business Unit)
  Person 2 Baynes, Roy (Merck(US) 201412 SVP Global Clinical Development)
     


   
Record changed: 2018-05-16

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px